A Randomized, Double Masked, Parallel Group, Dose-finding Study to Evaluate SYL1801 in Patients With Neovascular Age-related Macular Degeneration (AMD)

NCT05637255 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

99

Enrollment

INDUSTRY

Sponsor class

Conditions

Wet Macular Degeneration
Neovascular Age-related Macular Degeneration
Macular Degeneration

Interventions

DRUG: SYL1801

Sponsor

Sylentis, S.A.